dihexa parkinsons dihexa clinical trials status DIHEXA
Description
In vivo assessment of a delayed release formulation of larazotide acetate indicated for celiac disease using a porcine model
& Sur, M
Leads to secondary increases in IGF-1 and related downstream anabolic markers
Healthcare providers typically assess glycemic control, weight changes, kidney function, and overall tolerance to the medication
